Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2

Colavita Francesca, Brogi Alessandra, Lapa Daniele, Bordi Licia, Matusali Giulia, Meschi Silvia, Marsella Patrizia, Tesi Giulia, Bandini Tommaso, Di Caro Antonino, Capobianchi Maria Rosaria, Castilletti Concetta on behalf of the INMI Covid-19 laboratory team
doi: https://doi.org/10.1101/2020.05.24.20111682
Colavita Francesca
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brogi Alessandra
2DIESSE Diagnostica Senese S.p.A., Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lapa Daniele
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bordi Licia
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matusali Giulia
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meschi Silvia
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: silvia.meschi@inmi.it
Marsella Patrizia
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tesi Giulia
2DIESSE Diagnostica Senese S.p.A., Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bandini Tommaso
2DIESSE Diagnostica Senese S.p.A., Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Di Caro Antonino
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Capobianchi Maria Rosaria
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Castilletti Concetta
1National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Serological assays for anti-SARS-CoV-2 antibodies are now of critical importance to support diagnosis, guide epidemiological intervention, and understand immune response to natural infection and vaccine administration. We developed and validated new anti-SARS-CoV-2 IgG, IgM and IgA ELISA tests (ENZY-WELL SARS-CoV-2 ELISA, DIESSE Diagnostica Senese S.p.a.) based on whole-virus antigens. We used a total of 553 serum samples including samples from COVID-19 suspected and confirmed cases, healthy donors, and patients positive for other infections or autoimmune conditions. Overall, the assays showed good concordance with the indirect immunofluorescence reference test in terms of sensitivity and specificity. Especially for IgG and IgA, we observed high sensitivity (92.5 and 93.6%, respectively); specificity was high (>96%) for all antibody types ELISAs. In addition, sensitivity was linked to the days from symptoms onset (DSO) due to the seroconversion window, and for ENZY-WELL SARS-CoV-2 IgG and IgA ELISAs resulted 100% in those samples collected after 10 and 12 DSO, respectively. The results showed that ENZY-WELL SARS-CoV-2 ELISAs may represent a valid option for both diagnostic and epidemiological purposes, covering all different antibody types developed in SARS-CoV-2 immune response.

Competing Interest Statement

Alessandra Brogi, Giulia Tesi and Tommaso Bandini are employees of the DIESSE Diagnostica Senese S.p.a. (Siena, Italy). In no way their contribution to the completion of the study influenced the study design and the analysis of the results. No additional conflict of interest or other competing relationships exist.

Funding Statement

This research was carried out in the framework of a scientific collaboration between INMI and DIESSE Diagnostica Senese S.p.a. and supported by Ministry of Health (Ricerca Corrente and Conto Capitale 2017), and European Commission Horizon 2020 (European Virus Archive GLOBAL, 871029; EU project 101003544, CoNVat; EU project 101003551, EXSCALATE4CoV).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved from the INMI Ethical Board. Informed consent was not required as human samples used for this work were residual samples from routine diagnostic activities, patients' data remained anonymous, and the results obtained with the new tests were not used for the clinical management of the patient.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 26, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2
Colavita Francesca, Brogi Alessandra, Lapa Daniele, Bordi Licia, Matusali Giulia, Meschi Silvia, Marsella Patrizia, Tesi Giulia, Bandini Tommaso, Di Caro Antonino, Capobianchi Maria Rosaria, Castilletti Concetta
medRxiv 2020.05.24.20111682; doi: https://doi.org/10.1101/2020.05.24.20111682
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2
Colavita Francesca, Brogi Alessandra, Lapa Daniele, Bordi Licia, Matusali Giulia, Meschi Silvia, Marsella Patrizia, Tesi Giulia, Bandini Tommaso, Di Caro Antonino, Capobianchi Maria Rosaria, Castilletti Concetta
medRxiv 2020.05.24.20111682; doi: https://doi.org/10.1101/2020.05.24.20111682

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8989)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1904)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)